These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 27718369)

  • 1. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
    Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
    Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
    Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of adipokines in the rapid antidepressant effects of ketamine.
    Machado-Vieira R; Gold PW; Luckenbaugh DA; Ballard ED; Richards EM; Henter ID; De Sousa RT; Niciu MJ; Yuan P; Zarate CA
    Mol Psychiatry; 2017 Jan; 22(1):127-133. PubMed ID: 27046644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
    Niciu MJ; Shovestul BJ; Jaso BA; Farmer C; Luckenbaugh DA; Brutsche NE; Park LT; Ballard ED; Zarate CA
    J Affect Disord; 2018 May; 232():310-315. PubMed ID: 29501990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.
    Niciu MJ; Iadarola ND; Banerjee D; Luckenbaugh DA; Park M; Lener M; Park L; Ionescu DF; Ballard ED; Brutsche NE; Akula N; McMahon FJ; Machado-Vieira R; Nugent AC; Zarate CA
    J Psychopharmacol; 2017 Dec; 31(12):1570-1577. PubMed ID: 29039254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties.
    Duncan WC; Slonena E; Hejazi NS; Brutsche N; Yu KC; Park L; Ballard ED; Zarate CA
    Biol Psychiatry; 2017 Sep; 82(5):361-369. PubMed ID: 28457485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
    Chen MH; Cheng CM; Gueorguieva R; Lin WC; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Krystal JH; Su TP
    Neuropsychopharmacology; 2019 Nov; 44(12):2112-2118. PubMed ID: 31421635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
    Yang JJ; Wang N; Yang C; Shi JY; Yu HY; Hashimoto K
    Biol Psychiatry; 2015 Feb; 77(3):e19-e20. PubMed ID: 25104172
    [No Abstract]   [Full Text] [Related]  

  • 12. Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.
    Luckenbaugh DA; Ibrahim L; Brutsche N; Franco-Chaves J; Mathews D; Marquardt CA; Cassarly C; Zarate CA
    Bipolar Disord; 2012 Dec; 14(8):880-7. PubMed ID: 22978511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
    Nugent AC; Wills KE; Gilbert JR; Zarate CA
    Psychiatry Res Neuroimaging; 2019 Jan; 283():64-66. PubMed ID: 30551012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
    Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
    J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.
    Zarate CA; Brutsche N; Laje G; Luckenbaugh DA; Venkata SL; Ramamoorthy A; Moaddel R; Wainer IW
    Biol Psychiatry; 2012 Aug; 72(4):331-8. PubMed ID: 22516044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
    Sukhram SD; Yilmaz G; Gu J
    Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.